Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering

Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering PR Newswire

BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or "Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, today announced the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering price of $16.00 per share. The gross proceeds to Bambusa from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Bambusa, are expected to be $168,888,880. In addition, Bambusa has granted the underwriters a 30-day option to purchase up to an additional 1,583,333 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Bambusa.